The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.
VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.
Sleep Europe 2026 | One big question with Lucie Barateau: what to expect in hypersomnolence care in the next 5 years?
Lucie Barateau, MD, PhD, Gui-de-Chauliac Hospital, CHU Montpellier, Montpellier, France, discusses the advances she expects in hypersomnolence disorders over the next five years. Dr Barateau describes orexin receptor 2 (OX2R) agonists as a revolution in the field, with data in adults with narcolepsy type 1 (NT1) and studies emerging in narcolepsy type 2 (NT2) and pediatric populations. She also highlights the need for better phenotyping of NT2 and idiopathic hypersomnia, as many patients do not fit current diagnostic categories. This interview took place at Sleep Europe 2026 in Maastricht, the Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Orexin receptor 2 agonists, they are really a revolution in the field. So now we have nice data on adults, of course. We are waiting for others, but also orexin receptor 2 agonists in narcolepsy type 2 and NIH, this is coming, and in pediatric population. So I think this is the next five years coming for management. And as I said before, for the classifications, again, I think we need to go further in the phenotyping of narcolepsy type 2 and idiopathic hypersomnia to try to construct something different than these categories that we know and we have lots of patients that are not entering these categories so we have to redefine this and I think this is going to be a big work in the next few years...
Orexin receptor 2 agonists, they are really a revolution in the field. So now we have nice data on adults, of course. We are waiting for others, but also orexin receptor 2 agonists in narcolepsy type 2 and NIH, this is coming, and in pediatric population. So I think this is the next five years coming for management. And as I said before, for the classifications, again, I think we need to go further in the phenotyping of narcolepsy type 2 and idiopathic hypersomnia to try to construct something different than these categories that we know and we have lots of patients that are not entering these categories so we have to redefine this and I think this is going to be a big work in the next few years.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
